Cargando…
A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status
The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and ove...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104219/ https://www.ncbi.nlm.nih.gov/pubmed/30150877 http://dx.doi.org/10.1177/1179554918794672 |
_version_ | 1783349451279040512 |
---|---|
author | Su, Ying-Wen Hung, Chia-Yen Lam, Hung-Bun Chang, Yuan-Ching Yang, Po-Sheng |
author_facet | Su, Ying-Wen Hung, Chia-Yen Lam, Hung-Bun Chang, Yuan-Ching Yang, Po-Sheng |
author_sort | Su, Ying-Wen |
collection | PubMed |
description | The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and overall survival (OS) of patients with resected stage I-III TNBC who were treated with or without cisplatin-containing chemotherapy (CisCT or noCisCT) during 2004 and 2010. Of 129 patients, 25 received CisCT. In univariate analysis, the mean TTP for CisCT and noCisCT was 4.42 and 5.88 years, respectively (P = .004). The mean OS for CisCT and noCisCT was 6.76 and 9.63 years, respectively (P = .24). After adjusting for other clinicopathologic factors, only clinical stage II/III disease was independently associated with worse OS. The adjusted hazard ratio for CisCT was 1.48 (P = .46) and was not statistically significant. In this small retrospective study, adding cisplatin to adjuvant chemotherapy for early TNBC with unknown BRCA mutation status did not benefit OS. |
format | Online Article Text |
id | pubmed-6104219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61042192018-08-27 A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status Su, Ying-Wen Hung, Chia-Yen Lam, Hung-Bun Chang, Yuan-Ching Yang, Po-Sheng Clin Med Insights Oncol Triple-Negative Breast Cancer - Original Research The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and overall survival (OS) of patients with resected stage I-III TNBC who were treated with or without cisplatin-containing chemotherapy (CisCT or noCisCT) during 2004 and 2010. Of 129 patients, 25 received CisCT. In univariate analysis, the mean TTP for CisCT and noCisCT was 4.42 and 5.88 years, respectively (P = .004). The mean OS for CisCT and noCisCT was 6.76 and 9.63 years, respectively (P = .24). After adjusting for other clinicopathologic factors, only clinical stage II/III disease was independently associated with worse OS. The adjusted hazard ratio for CisCT was 1.48 (P = .46) and was not statistically significant. In this small retrospective study, adding cisplatin to adjuvant chemotherapy for early TNBC with unknown BRCA mutation status did not benefit OS. SAGE Publications 2018-08-21 /pmc/articles/PMC6104219/ /pubmed/30150877 http://dx.doi.org/10.1177/1179554918794672 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Triple-Negative Breast Cancer - Original Research Su, Ying-Wen Hung, Chia-Yen Lam, Hung-Bun Chang, Yuan-Ching Yang, Po-Sheng A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status |
title | A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status |
title_full | A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status |
title_fullStr | A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status |
title_full_unstemmed | A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status |
title_short | A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status |
title_sort | single institution experience of incorporation of cisplatin into adjuvant chemotherapy for patients with triple-negative breast cancer of unknown brca mutation status |
topic | Triple-Negative Breast Cancer - Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104219/ https://www.ncbi.nlm.nih.gov/pubmed/30150877 http://dx.doi.org/10.1177/1179554918794672 |
work_keys_str_mv | AT suyingwen asingleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT hungchiayen asingleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT lamhungbun asingleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT changyuanching asingleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT yangposheng asingleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT suyingwen singleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT hungchiayen singleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT lamhungbun singleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT changyuanching singleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus AT yangposheng singleinstitutionexperienceofincorporationofcisplatinintoadjuvantchemotherapyforpatientswithtriplenegativebreastcancerofunknownbrcamutationstatus |